Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Cerevance’s NETSseq technology platform has isolated and allowed for analysis of specific cell populations in thousands of post-mortem, healthy and diseased human brain tissue samples across a range of ages and brain regions.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: $1,125.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration August 09, 2022
Details:
Under the terms of the collaboration, Plexium will conduct preclinical research activities for the collaboration targets, after which AbbVie has the option to select programs for additional research and development activities.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $565.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2022
Details:
Under the terms of the agreement, Novartis has the right to evaluate novel capsids from Voyager’s TRACER platform and to exercise options to license capsids for exclusive use with specific targets in Novartis’ development of AAV gene therapies.
Lead Product(s): AAV-based Capsid
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,754.0 million Upfront Cash: $54.0 million
Deal Type: Licensing Agreement March 08, 2022
Details:
This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $257.5 million Upfront Cash: $10.0 million
Deal Type: Collaboration December 21, 2021
Details:
Funding from the Series B will be used to exponentially grow the number of preclinical and clinical programs in Verge’s pipeline and advance its lead programs through clinical testing.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: BlackRock
Deal Size: $98.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 16, 2021
Details:
Recursion will work with both Roche and Genentech's R&D units to leverage technology-enabled drug discovery through the Recursion Operating System to more rapidly identify novel targets and advance medicines in key areas of neuroscience as well as in an oncology indication.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $12,150.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration December 07, 2021
Details:
As part of the collaboration, Secarna will employ its commercially validated discovery and development platform, LNAplus™ to generate antisense oligonucleotide candidates against targets relevant for the treatment of neurodegenerative diseases.
Lead Product(s): Antisense Oligonucleotides
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Secarna Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 26, 2021
Details:
During the course of the partnership, ShapeTX will conduct preclinical research to identify and deliver development candidates discovered by its AI-powered platforms RNAfix™ and, potentially, AAVid™.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $3,000.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2021
Details:
Rgenta will use its novel and integrative discovery platform to identify and optimize RNA-targeting small molecules against high-value targets. Rgenta will grant Lundbeck license of candidate molecules, which will be developed and commercialized by Lundbeck.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: $110.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration August 04, 2021
Details:
Under the agreement, CRISPR Therapeutics will lead R&D of the Friedreich’s ataxia program and perform gene-editing activities for both programs, and Capsida will lead research and development of the ALS program and conduct AAV vectors engineering for both programs.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Capsida
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 15, 2021
